View ValuationDocMorris 향후 성장Future 기준 점검 1/6DocMorris (는) 각각 연간 65.3% 및 9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 76.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -16% 로 예상됩니다.핵심 정보65.3%이익 성장률76.90%EPS 성장률Consumer Retailing 이익 성장9.0%매출 성장률9.0%향후 자기자본이익률-15.98%애널리스트 커버리지Good마지막 업데이트25 Apr 2026최근 향후 성장 업데이트공시 • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.공시 • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.Breakeven Date Change • Aug 23The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Breakeven Date Change • Dec 23No longer forecast to breakevenThe 8 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF2.23m in 2023.Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 9 analysts covering Zur Rose Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CHF22.7m in 2023. Average annual earnings growth of 62% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates공시 • Apr 17DocMorris AG, Annual General Meeting, May 12, 2026DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time.Reported Earnings • Mar 19Full year 2025 earnings released: CHF3.47 loss per share (vs CHF8.25 loss in FY 2024)Full year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Consumer Retailing industry in the United Kingdom.New Risk • Jan 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (277% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF28m net loss in 3 years). Share price has been volatile over the past 3 months (7.0% average weekly change).공시 • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.Reported Earnings • Aug 20Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024)Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Consumer Retailing industry in the United Kingdom.공시 • May 23DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. Security Name: Shares Security Type: Common Stock Securities Offered: 36,182,790 Price\Range: CHF 5.75 Transaction Features: Rights Offering공시 • May 22DocMorris AG announced that it expects to receive funding from Pelion S.A.DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issueNew Risk • May 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 285% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF93m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (285% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF26m net loss in 3 years).Reported Earnings • May 09First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024)First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Rongrong Hu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026공시 • Apr 15DocMorris AG, Annual General Meeting, May 08, 2025DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time.공시 • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.Reported Earnings • Mar 14First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.New Risk • Jan 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF17m net loss in 3 years).Reported Earnings • Aug 23First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 23The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF97m Forecast net loss in 3 years: CHF387k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF387k net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).New Risk • Aug 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).공시 • Jul 12+ 1 more updateDocMorris AG to Report First Half, 2025 Results on Aug 19, 2025DocMorris AG announced that they will report first half, 2025 results on Aug 19, 2025공시 • Jun 20DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025New Risk • May 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Share price has been volatile over the past 3 months (8.0% average weekly change). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).Reported Earnings • Mar 24Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF969.5m (up 4.1% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.New Risk • Mar 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).New Risk • Oct 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF852k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF852k net loss in 3 years). Share price has been volatile over the past 3 months (7.4% average weekly change).공시 • Sep 22+ 2 more updatesDocMorris AG to Report Fiscal Year 2023 Results on Mar 21, 2024DocMorris AG announced that they will report fiscal year 2023 results on Mar 21, 2024New Risk • Aug 28New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF344k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF344k net loss in 3 years). Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding).Reported Earnings • Aug 20First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022)First half 2023 results: CHF4.99 loss per share (improved from CHF8.05 loss in 1H 2022). Revenue: CHF463.0m (down 6.4% from 1H 2022). Net loss: CHF58.2m (loss narrowed 30% from 1H 2022). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.공시 • May 05Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG agreed to acquire Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. The proceeds from the sale of approximately CHF 360 million in cash comprise a first tranche upon completion of the transaction, expected in the second quarter of 2023, and an earnout of CHF 47 million based on the achievement of Zur Rose Switzerland's 2023 EBITDA target, payable in the second quarter of 2024. Zur Rose Switzerland achieved revenue of CHF 687 million in 2022.The transaction is expected to close in the second quarter of 2023, subject to approval by the competition authority. As on April 28, 2023 Competition commission validated the transaction. Matthias Courvoisier, Olha Demianiuk, Yves Mauchle, Beau Visser, Roger Thomi, Bettina Klein, Victoria Brammer and Victoria Hotz of Baker & McKenzie (Zurich) acted as legal advisor to Zur Rose Group AG. Morgan Stanley (NYSE:MS) and Enqcor AG acted as financial advisor to Zur Rose Group AG (SWX:ROSE).Bär & Karrer Ltd. acted as legal advisor to Medbase AG . Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on May 4, 2023. Medbase is taking over all the Zur Rose Group's operational units in Switzerland excluding land and properties with all employees.공시 • Feb 03Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Reported Earnings • Aug 19First half 2022 earnings released: CHF8.29 loss per share (vs CHF8.03 loss in 1H 2021)First half 2022 results: CHF8.29 loss per share (down from CHF8.03 loss in 1H 2021). Revenue: CHF840.3m (flat on 1H 2021). Net loss: CHF86.1m (loss widened 12% from 1H 2021). Over the next year, revenue is forecast to grow 15%, compared to a 5.8% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.공시 • Jul 14+ 2 more updatesZur Rose Group AG, Annual General Meeting, May 04, 2023Zur Rose Group AG, Annual General Meeting, May 04, 2023, at 17:00 Central European Standard Time.Breakeven Date Change • Dec 23No longer forecast to breakevenThe 8 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF2.23m in 2023.Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 9 analysts covering Zur Rose Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CHF22.7m in 2023. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Reported Earnings • Aug 21First half 2021 earnings released: CHF8.03 loss per share (vs CHF6.03 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF839.8m (up 20% from 1H 2020). Net loss: CHF77.0m (loss widened 47% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.Breakeven Date Change • Jun 13No longer forecast to breakevenThe 9 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF14.2m in 2023.Executive Departure • May 04Non-Executive Director has left the companyOn the 29th of April, Tobias Hartmann's tenure as Non-Executive Director ended after 1.9 years in the role. As of December 2020, Tobias personally held 394.00 shares (CHF110k worth at the time). Tobias is the only executive to leave the company over the last 12 months.Reported Earnings • Apr 10Full year 2020 earnings released: CHF14.95 loss per share (vs CHF6.04 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.7m (loss widened 159% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings.Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.6m (loss widened 159% from FY 2019).Is New 90 Day High Low • Feb 07New 90-day high: CHF465The company is up 71% from its price of CHF273 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,030 per share.Is New 90 Day High Low • Jan 22New 90-day high: CHF410The company is up 74% from its price of CHF235 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: CHF286The company is up 27% from its price of CHF226 on 07 October 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Dec 07New 90-day low: CHF124The company is down 42% from its price of CHF213 on 08 September 2020. The British market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 07New 90-day low: CHF124The company is down 53% from its price of CHF262 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF31.15 per share.공시 • Aug 19Zur Rose Group AG to Report Fiscal Year 2020 Results on Mar 18, 2021Zur Rose Group AG announced that they will report fiscal year 2020 results on Mar 18, 2021공시 • Aug 18Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de.Zur Rose Group AG (SWX:ROSE) agreed to acquire AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on June 26, 2020. AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH formed the Mail-order and Diabetes Activities of Apotal Group. The acquisition is financed from available cash and up to 60% of the purchase price by issuing new shares funded from the authorized and conditional capital. As part of the transaction, Heinz-Peter Fichter will become a shareholder and future consultant of Zur Rose Group, Henning Fichter will be the managing director of the diabetes division and 1.1 million active customers will be transferred to Zur Rose subject to giving their consent. The transaction is subject to approval by the German Federal Cartel Office and expected to close in third quarter of 2020. Johannes H. Lucas of ACXIT Capital Partners acted as financial advisor to Zur Rose. Klaus Krink, Sönke Storch, Björn Schallock, Albrecht von Bismarck, Jörn Karall and Stephan Weber of Ebner Stolz acted as legal advisor and Alvarez & Marsal Securities, LLC provided due diligence to Zur Rose. Christoph Smile, Jochen Lux, Boris Alles, Heralt Hug, Jörn Witt, Susanne Pech, Dirk Schauer, Martin Mohr and Rolf Hempel of CMS Germany and Daniel Jenny of CMS Switzerland acted as legal advisor to Heinz-Peter Fichter, founder of Apotal Group and other partners. FERBER & CO. GmbH acted as financial advisor to Apotal Group and Heinz-Peter Fichter. Clemens Krämer of Dorn Krämer & Partner acted as legal advisor for Zur Rose. Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on August 17, 2020. For payment of the share portion of the purchase price, Zur Rose issued 0.13 million shares.공시 • Jul 18+ 1 more updateZur Rose Group AG has completed a Follow-on Equity Offering in the amount of CHF 212.616201 million.Zur Rose Group AG has completed a Follow-on Equity Offering in the amount of CHF 212.616201 million. Security Name: Shares Security Type: Common Stock Securities Offered: 740,823 Price\Range: CHF 287 Transaction Features: Subsequent Direct Listing이익 및 매출 성장 예측LSE:0RRB - 애널리스트 향후 추정치 및 과거 재무 데이터 (CHF Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,463-23-1830612/31/20271,369-48-35-2812/31/20261,218-84-71-45612/31/20251,124-134-116-89N/A9/30/20251,093-128-108-80N/A6/30/20251,062-121-99-71N/A3/31/20251,052-114-93-64N/A12/31/20241,017-97-55-27N/A9/30/20241,010-97-75-45N/A6/30/20241,003-97-95-63N/A3/31/2024984-97-88-57N/A12/31/2023969-118-119-87N/A9/30/2023934-132-124-90N/A6/30/2023899-146-129-93N/A3/31/2023915-158-136-95N/A12/31/2022931-171-144-97N/A9/30/20221,156-202-178-126N/A6/30/20221,381-232-212-155N/A3/31/20221,554-229-203-143N/A12/31/20211,727-226-194-131N/A9/30/20211,673-193-155-87N/A6/30/20211,619-160-116-43N/A3/31/20211,548-148-122-55N/A12/31/20201,477-136-127-68N/A9/30/20201,431-112-138-88N/A6/30/20201,385-88-149-108N/A3/31/20201,370-70-137-95N/A12/31/20191,356-52-124-83N/A9/30/20191,314-45N/AN/AN/A6/30/20191,272-39N/A-35N/A3/31/20191,240-39N/A-34N/A12/31/20181,207-39N/A-33N/A9/30/20181,166-37N/AN/AN/A6/30/20181,125-36N/A-30N/A3/31/20181,061-36N/AN/AN/A12/31/2017990-36N/A-22N/A9/30/2017953-34N/A-21N/A6/30/2017915-31N/A-21N/A3/31/2017900-21N/AN/AN/A12/31/2016884-13N/A-14N/A9/30/2016873-4N/AN/AN/A6/30/20168616N/AN/AN/A3/31/20168474N/AN/AN/A12/31/20158383N/A19N/A9/30/20158574N/AN/AN/A6/30/20158755N/AN/AN/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 0RRB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 0RRB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 0RRB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 0RRB 의 수익(연간 9%)이 UK 시장(연간 4.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 0RRB 의 수익(연간 9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 0RRB는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YConsumer-retailing 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 13:02종가2026/05/20 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스DocMorris AG는 19명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Volker BosseBaader Helvea Equity ResearchSarah RobertsBarclaysGuillaume GallandBarclays16명의 분석가 더 보기
공시 • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.
공시 • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.
Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.
Breakeven Date Change • Aug 23The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Breakeven Date Change • Dec 23No longer forecast to breakevenThe 8 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF2.23m in 2023.
Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 9 analysts covering Zur Rose Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CHF22.7m in 2023. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
공시 • Apr 17DocMorris AG, Annual General Meeting, May 12, 2026DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time.
Reported Earnings • Mar 19Full year 2025 earnings released: CHF3.47 loss per share (vs CHF8.25 loss in FY 2024)Full year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Consumer Retailing industry in the United Kingdom.
New Risk • Jan 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (277% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF28m net loss in 3 years). Share price has been volatile over the past 3 months (7.0% average weekly change).
공시 • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.
Reported Earnings • Aug 20Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024)Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Consumer Retailing industry in the United Kingdom.
공시 • May 23DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. Security Name: Shares Security Type: Common Stock Securities Offered: 36,182,790 Price\Range: CHF 5.75 Transaction Features: Rights Offering
공시 • May 22DocMorris AG announced that it expects to receive funding from Pelion S.A.DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issue
New Risk • May 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 285% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF93m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (285% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF26m net loss in 3 years).
Reported Earnings • May 09First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024)First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Rongrong Hu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026
공시 • Apr 15DocMorris AG, Annual General Meeting, May 08, 2025DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time.
공시 • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.
Reported Earnings • Mar 14First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 13No longer forecast to breakevenThe 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027.
New Risk • Jan 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF17m net loss in 3 years).
Reported Earnings • Aug 23First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 23The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF97m Forecast net loss in 3 years: CHF387k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF387k net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).
New Risk • Aug 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).
공시 • Jul 12+ 1 more updateDocMorris AG to Report First Half, 2025 Results on Aug 19, 2025DocMorris AG announced that they will report first half, 2025 results on Aug 19, 2025
공시 • Jun 20DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025
New Risk • May 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Share price has been volatile over the past 3 months (8.0% average weekly change). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).
Reported Earnings • Mar 24Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF969.5m (up 4.1% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
New Risk • Mar 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
New Risk • Oct 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF852k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF852k net loss in 3 years). Share price has been volatile over the past 3 months (7.4% average weekly change).
공시 • Sep 22+ 2 more updatesDocMorris AG to Report Fiscal Year 2023 Results on Mar 21, 2024DocMorris AG announced that they will report fiscal year 2023 results on Mar 21, 2024
New Risk • Aug 28New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF344k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF344k net loss in 3 years). Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding).
Reported Earnings • Aug 20First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022)First half 2023 results: CHF4.99 loss per share (improved from CHF8.05 loss in 1H 2022). Revenue: CHF463.0m (down 6.4% from 1H 2022). Net loss: CHF58.2m (loss narrowed 30% from 1H 2022). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
공시 • May 05Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG agreed to acquire Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. The proceeds from the sale of approximately CHF 360 million in cash comprise a first tranche upon completion of the transaction, expected in the second quarter of 2023, and an earnout of CHF 47 million based on the achievement of Zur Rose Switzerland's 2023 EBITDA target, payable in the second quarter of 2024. Zur Rose Switzerland achieved revenue of CHF 687 million in 2022.The transaction is expected to close in the second quarter of 2023, subject to approval by the competition authority. As on April 28, 2023 Competition commission validated the transaction. Matthias Courvoisier, Olha Demianiuk, Yves Mauchle, Beau Visser, Roger Thomi, Bettina Klein, Victoria Brammer and Victoria Hotz of Baker & McKenzie (Zurich) acted as legal advisor to Zur Rose Group AG. Morgan Stanley (NYSE:MS) and Enqcor AG acted as financial advisor to Zur Rose Group AG (SWX:ROSE).Bär & Karrer Ltd. acted as legal advisor to Medbase AG . Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on May 4, 2023. Medbase is taking over all the Zur Rose Group's operational units in Switzerland excluding land and properties with all employees.
공시 • Feb 03Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.
Reported Earnings • Aug 19First half 2022 earnings released: CHF8.29 loss per share (vs CHF8.03 loss in 1H 2021)First half 2022 results: CHF8.29 loss per share (down from CHF8.03 loss in 1H 2021). Revenue: CHF840.3m (flat on 1H 2021). Net loss: CHF86.1m (loss widened 12% from 1H 2021). Over the next year, revenue is forecast to grow 15%, compared to a 5.8% growth forecast for the Consumer Retailing industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
공시 • Jul 14+ 2 more updatesZur Rose Group AG, Annual General Meeting, May 04, 2023Zur Rose Group AG, Annual General Meeting, May 04, 2023, at 17:00 Central European Standard Time.
Breakeven Date Change • Dec 23No longer forecast to breakevenThe 8 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF2.23m in 2023.
Breakeven Date Change • Sep 23Forecast to breakeven in 2023The 9 analysts covering Zur Rose Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CHF22.7m in 2023. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Reported Earnings • Aug 21First half 2021 earnings released: CHF8.03 loss per share (vs CHF6.03 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF839.8m (up 20% from 1H 2020). Net loss: CHF77.0m (loss widened 47% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.
Breakeven Date Change • Jun 13No longer forecast to breakevenThe 9 analysts covering Zur Rose Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF16.8m in 2023. New consensus forecast suggests the company will make a loss of CHF14.2m in 2023.
Executive Departure • May 04Non-Executive Director has left the companyOn the 29th of April, Tobias Hartmann's tenure as Non-Executive Director ended after 1.9 years in the role. As of December 2020, Tobias personally held 394.00 shares (CHF110k worth at the time). Tobias is the only executive to leave the company over the last 12 months.
Reported Earnings • Apr 10Full year 2020 earnings released: CHF14.95 loss per share (vs CHF6.04 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.7m (loss widened 159% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 48% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 20Full year 2020 earnings releasedThe company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF1.48b (up 9.0% from FY 2019). Net loss: CHF135.6m (loss widened 159% from FY 2019).
Is New 90 Day High Low • Feb 07New 90-day high: CHF465The company is up 71% from its price of CHF273 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,030 per share.
Is New 90 Day High Low • Jan 22New 90-day high: CHF410The company is up 74% from its price of CHF235 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: CHF286The company is up 27% from its price of CHF226 on 07 October 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Dec 07New 90-day low: CHF124The company is down 42% from its price of CHF213 on 08 September 2020. The British market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 07New 90-day low: CHF124The company is down 53% from its price of CHF262 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF31.15 per share.
공시 • Aug 19Zur Rose Group AG to Report Fiscal Year 2020 Results on Mar 18, 2021Zur Rose Group AG announced that they will report fiscal year 2020 results on Mar 18, 2021
공시 • Aug 18Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de.Zur Rose Group AG (SWX:ROSE) agreed to acquire AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on June 26, 2020. AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH formed the Mail-order and Diabetes Activities of Apotal Group. The acquisition is financed from available cash and up to 60% of the purchase price by issuing new shares funded from the authorized and conditional capital. As part of the transaction, Heinz-Peter Fichter will become a shareholder and future consultant of Zur Rose Group, Henning Fichter will be the managing director of the diabetes division and 1.1 million active customers will be transferred to Zur Rose subject to giving their consent. The transaction is subject to approval by the German Federal Cartel Office and expected to close in third quarter of 2020. Johannes H. Lucas of ACXIT Capital Partners acted as financial advisor to Zur Rose. Klaus Krink, Sönke Storch, Björn Schallock, Albrecht von Bismarck, Jörn Karall and Stephan Weber of Ebner Stolz acted as legal advisor and Alvarez & Marsal Securities, LLC provided due diligence to Zur Rose. Christoph Smile, Jochen Lux, Boris Alles, Heralt Hug, Jörn Witt, Susanne Pech, Dirk Schauer, Martin Mohr and Rolf Hempel of CMS Germany and Daniel Jenny of CMS Switzerland acted as legal advisor to Heinz-Peter Fichter, founder of Apotal Group and other partners. FERBER & CO. GmbH acted as financial advisor to Apotal Group and Heinz-Peter Fichter. Clemens Krämer of Dorn Krämer & Partner acted as legal advisor for Zur Rose. Zur Rose Group AG (SWX:ROSE) completed the acquisition of AdBest Werbeagentur GmbH, Ultra Pharm Medicalprodukte Gmbh and Dia Plus Minus Handelsgesellschaft mbH from apotal.de on August 17, 2020. For payment of the share portion of the purchase price, Zur Rose issued 0.13 million shares.
공시 • Jul 18+ 1 more updateZur Rose Group AG has completed a Follow-on Equity Offering in the amount of CHF 212.616201 million.Zur Rose Group AG has completed a Follow-on Equity Offering in the amount of CHF 212.616201 million. Security Name: Shares Security Type: Common Stock Securities Offered: 740,823 Price\Range: CHF 287 Transaction Features: Subsequent Direct Listing